DarioHealth

DRIO

Capitalización de mercado USD 47.2 M

A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users Evaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life population Aon estimates an additional 1.6 to 2.8 percentage points of potential healthcare cost savings as a result of providing direct access to physicians while simultaneously managing multiple chronic conditions, for potential total of 10% annual savings Independent analysis finds that evidence supports the economic value of Dario's multi-condition digital health platform for payers including employers, health plans, health systems and accountable care organizations (ACOs) NEW YORK, Oct. 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the results of a review titled "An Independent Review of Evidence Supporting DarioHealth's Clinical and Cost-Savings Impact" conducted by the Managed Care Services Team of Aon plc ("Aon"), a leading global professional services firm. Based upon its review of data provided by Dario and published studies identified by Dario, Aon's Managed Care Services Team concluded that the evidence reviewed supports an estimated reduction in total healthcare costs of 2.5% to 7.2% annually across a covered population – measured against total healthcare spend, not only the spend of program participants.

Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027 Marks the third large state health plan signed through Amwell in the past 12 months, following contracts in Arizona and Florida NEW YORK, Sept. 17, 2026 /PRNewswire/ -- DarioHealth Corp.  (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives.

DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript

DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business.

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition Commercial momentum with three significant wins in recent weeks, led by a top-5 national health plan expansion with the potential to approximately triple Dario's potential revenue opportunity — its third such expansion — plus a 5th Fortune 50 client and a new health insurer via the Amwell channel Expanded into provider-backed clinical care delivery, accessing a larger portion of the healthcare value chain and increasing the potential revenue opportunity per client Pro forma cash of $36.8 million following $22.8 million net proceeds from at-the-market registered direct financing with participation from existing long-term shareholders and new fundamental institutional investors completed in July 2026 Conference call today, August 11, 2026 at 8:30 am ET NEW YORK, Aug. 11, 2026 /PRNewswire/ -- DarioHealth  Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the second quarter ended June 30, 2026. "We believe that Dario has reached an important stage where the investments made in our technology, product, and distribution infrastructure are compounding positive momentum," said Erez Raphael, Chief Executive Officer of Dario.

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services NEW YORK, Aug. 4, 2026 /PRNewswire/ --  DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed healthcare providers.

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2026 and will host a conference call and webcast at 8:30 a.m.

First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Commercial availability expected Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027 Launch addresses a market in which employers and health plans are reducing GLP-1 coverage and members are increasingly accessing care through consumer channels Available through three channels: Dario's direct-to-consumer shop, health plan marketplaces and employer B2B2C programs NEW YORK, July 30, 2026 /PRNewswire/ --  DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the launch of Dario's Integrated GLP-1 Program, the first commercial offering built on the Company's recently announced collaboration with Beluga Health ("Beluga"). Dario has supported members on GLP-1 therapy for years through AI-powered engagement, connected monitoring, nutrition and behavioral coaching.

DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.